StockTipsArenaBeta

BUY Cipla Ltd. — Ansh Jogendra Bhilwar

BUYCipla Ltd.
Cipla share price target & all analyst calls

byAnsh Jogendra BhilwarHorizon: NA (inferred Swing (≤2wk))1 Sept 2026via Zee Business Stocks

Entry₹1,420.9Inferred
Target₹1,488
Total upside +4.72% (call closed)
Stop loss₹1,373-3.37% risk
Exit₹1,3739 Sept 2026, 10:45 am
Stop-loss hit-3.37%
Follow Ansh Jogendra Bhilwar for new calls(25% target hit, 72 closed calls)Get alertsWatch CIPLA for new buy/sell callsGet alertsSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 9 Sept 2026
8 supporting7 neutral4 opposing
Supports the BUY call (8)

Explained: Why Morgan Stanley has the second-lowest price target on the Street for this drugmaker

NewsCnbc-Tv18·4 Sept · 4d ago

(opens in new tab)

Cipla announces exclusive US partnership with Qilu Pharma for keytruda biosimilar

NewsCnbc-Tv18·3 Sept · 5d ago

(opens in new tab)

Cipla announces an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to Keytruda (Pembrolizumab) in the US.

BSE · Company Update·3 Sept · 5d ago

(opens in new tab)

Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix

NewsCnbc-Tv18·1 Sept · 1w ago

(opens in new tab)

Cipla shares gain after it inks cancer treatment drug licensing deal with Sino Biopharma arm

NewsCnbc-Tv18·1 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (7)

Cipla Ltd is intimating shareholders and creditors about a notice regarding a Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited with Cipla Limited. The notice provides an opport

BSE · Company Update·3 Sept · 5d ago

(opens in new tab)

US FDA classifies Cipla subsidiary’s New York facility inspection as ‘Voluntary Action Indicated’

NewsCnbc-Tv18·29 Aug · 1w ago

(opens in new tab)

Cipla Pharma License Cancellation: FDA Withdraws Order After HC Raps It For Going "Overboard"

NewsNdtv-Profit·29 Aug · 1w ago

(opens in new tab)

Cipla shares slip after USFDA observations; Citi says no earnings impact, target at ₹1,700

NewsCnbc-Tv18·26 Aug · 2w ago

(opens in new tab)

Nifty, Sensex open lower on Iran sanctions, tech selloff; TCS, Eternal gain while Cipla, Maruti slip

NewsHbl·25 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (4)

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

NewsHbl·4 Sept · 4d ago

(opens in new tab)

Cipla Pharma license cancellation: FDA withdraws order after Bombay HC raps it for going 'overboard'

NewsCnbc-Tv18·29 Aug · 1w ago

(opens in new tab)

FDA Crackdown: Cipla Arm Loses Pune Drug Sales Licence For Storage Deficiencies, Illegal Ads

NewsNdtv-Profit·28 Aug · 2w ago

(opens in new tab)

Cipla gets seven USFDA observations for Pithampur plant after follow-up inspection

NewsCnbc-Tv18·25 Aug · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cipla

All analyst calls on Cipla

More from Ansh Jogendra Bhilwar

Every call and its outcome